HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

mesdopetam

a dopamine d3 receptor antagonist.

Also Known As:

IRL790; N-(2-(3-fluoro-5-methylsulfonylphenoxy)ethyl)propan-1-amine

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Tedroff, Joakim: 3 articles (01/2020 - 01/2018)
2.	Sonesson, Clas: 2 articles (01/2020 - 01/2018)
3.	Svenningsson, Per: 2 articles (01/2020 - 01/2018)
4.	Becanovic, Kristina: 1 article (01/2020)
5.	Carta, Manolo: 1 article (01/2020)
6.	Edling, Malin: 1 article (01/2020)
7.	Fagerberg, Anne: 1 article (01/2020)
8.	Gunnergren, Jenny: 1 article (01/2020)
9.	Hjorth, Stephan: 1 article (01/2020)
10.	Kullingsjö, Johan: 1 article (01/2020)

Related Diseases

1.	Dyskinesias (Dyskinesia) 01/01/2018 - "PD patients with peak-dose dyskinesia were randomized to placebo or IRL790 treatment (1:3 ratio) for 4 weeks. " 01/01/2018 - "Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial." 01/01/2020 - "IRL790 is active in models of perturbed dopaminergic and glutamatergic signaling, including rodent 6-hydroxydopamine l-DOPA-induced dyskinesias and psychostimulant-induced hyperactivity, in a dose range that does not impair normal behavior. " 01/01/2020 - "SIGNIFICANCE STATEMENT: The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. " 01/01/2020 - "The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. "
2.	Parkinson Disease (Parkinson's Disease) 01/01/2020 - "SIGNIFICANCE STATEMENT: This paper reports preclinical pharmacology along with molecular modeling results on IRL790, a novel compound in clinical development for the treatment of motor and psychiatric complications in advanced Parkinson disease. " 01/01/2018 - "Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial." 01/01/2020 - "Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease." 01/01/2020 - "SIGNIFICANCE STATEMENT: The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. " 01/01/2020 - "The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. "
3.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2020 - "SIGNIFICANCE STATEMENT: The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. " 01/01/2020 - "The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. " 01/01/2018 - "IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson's disease (PD). "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	mesdopetam
3.	Oxidopamine (6 Hydroxydopamine)
4.	Dizocilpine Maleate (Dizocilpine)
5.	Dopamine (Intropin)
6.	Dextroamphetamine (Dexedrine)
7.	Amines